Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 10/20 | 0.40 |
| ▸ | LTB4R2 | Q9NPC1 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11012956 | 0.89 | L3MBTL1 (0.41) | CYP4F2CYP4A11L3MBTL1TDP1LTB4R | |
| SCHEMBL6370919 | 0.85 | LTB4R (0.48) | LTB4RLTB4R2PPARGPPARA | |
| SCHEMBL30982179 | 0.82 | CYP4F2 (0.52) | CYP4F2CYP4A11L3MBTL1TDP1CTDSP1 | |
| SCHEMBL14046828 | 0.82 | CYP4F2 (0.52) | CYP4F2CYP4A11L3MBTL1TDP1CTDSP1 | |
| SCHEMBL4246764 | 0.82 | CYP4F2 (0.52) | CYP4F2CYP4A11L3MBTL1TDP1CTDSP1 | |
| SCHEMBL7314503 | 0.81 | TDP1 (0.56) | CYP4F2CYP4A11L3MBTL1TDP1CTDSP1 | |
| SCHEMBL8587477 | 0.80 | LTB4R (0.50) | CYP4F2CYP4A11LTB4RLTB4R2 | |
| SCHEMBL14092138 | 0.80 | CYP4F2 (0.52) | CYP4F2CYP4A11L3MBTL1TDP1CTDSP1 | |
| SCHEMBL14046824 | 0.79 | CYP4F2 (0.48) | CYP4F2CYP4A11L3MBTL1TDP1CTDSP1 | |
| SCHEMBL9739640 | 0.77 | CYP4F2 (0.67) | CYP4F2CYP4A11L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0579412-B1 | 1,2,4-trioxygenated benzene derivatives useful as a leukotriene antagonists | LILLY CO ELI (US) | 1998-10-07 | — | — | EP | disclosed |
| EP-0735870-A4 | USE OF PLA 2? INHIBITORS AS TREATMENT FOR ALZHEIMER'S DISEASE | LILLY CO ELI (US) | 1998-08-19 | — | — | EP | disclosed |
| EP-0735870-A1 | USE OF PLA 2? INHIBITORS AS TREATMENT FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1996-10-09 | — | — | EP | disclosed |
| US-5563164-A | TREATING ARTHRITIS, PSORIASIS, ASTHMA, INFLAMMATORY BOWEL DISEASE, OR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1996-10-08 | — | — | US | disclosed |
| US-5552441-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS AND RESPIRATORY SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1996-09-03 | — | — | US | disclosed |
| US-5478857-A | Administering inhibitor of phospholipase A2 | ELI LILLY AND COMPANY (US) | 1995-12-26 | — | — | US | disclosed |
| WO-1995017183-A1 | USE OF PLA2 INHIBITORS AS TREATMENT FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1995-06-29 | — | — | WO | disclosed |
| US-5352690-A | For asthma, allergies | ELI LILLY AND COMPANY (US) | 1994-10-04 | — | — | US | disclosed |
| US-5324743-A | Leukotriene B4 antagonists | ELI LILLY AND COMPANY (US) | 1994-06-28 | — | — | US | disclosed |
| EP-0579412-A1 | 1,2,4-trioxygenated benzene derivatives useful as a leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1994-01-19 | — | — | EP | disclosed |